Loading
NASDAQHealthcareBiotechnology
Latest quote
$3.0501
+$0.0001 · +0.00%
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
Regular session
$3.0501
+$0.0001 · +0.00%
Regular session · ET · Market data may be delayed.
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
Day range
Current $3.0501
52-week range
Current $3.0501
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
94
Deep Value
Sentiment
41
Mixed
Risk
69
High Risk
Momentum
18
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
Day range
Current $3.0501
52-week range
Current $3.0501
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 7.53M USD | 3.34M USD | 73K USD | — | — |
| Gross profit | 7.53M USD | 3.34M USD | 73K USD | — | — |
| Research and development | 9.98M USD | 10.46M USD | 11.92M USD | 17.06M USD | 19.58M USD |
| Selling, general, and administrative | 6.49M USD | 7.32M USD | 10.08M USD | 8.06M USD | 6.18M USD |
| Operating expenses | 16.76M USD | 18.08M USD | 22.27M USD | 25.26M USD | 25.83M USD |
| Interest income | 299K USD | 254K USD | 154K USD | 2.83M USD | 2.04M USD |
| Interest expense | 876K USD | 962K USD | 897K USD | 1.51M USD | 915K USD |
| Depreciation and amortization | 615K USD | 607K USD | 615K USD | 571K USD | 344K USD |
| Operating income | −9.23M USD | −14.73M USD | −22.2M USD | −25.26M USD | −25.83M USD |
| Net income | −7.71M USD | −10.57M USD | −22.13M USD | −23.17M USD | −24.53M USD |
Company facts updated Oct 9, 2026.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
